Intellectual Property and Biopharmaceuticals

The Biden administration and members of Congress have proposed reducing protections on intellectual property to lower drug prices. However, these policies could affect academic institutions and investment in US innovation without meaningfully reducing drug prices. Specifically, proposals to relax patent protections further risk discouraging public and private partnerships and industry investment.